KeyMed Biosciences Inc
HKEX:2162
Cash Flow Statement
Cash Flow Statement
KeyMed Biosciences Inc
| Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||
| Net Income |
(3 893)
|
(260)
|
(304)
|
(258)
|
(356)
|
(735)
|
(509)
|
(254)
|
|
| Depreciation & Amortization |
21
|
25
|
36
|
48
|
69
|
89
|
93
|
96
|
|
| Stock-Based Compensation |
117
|
131
|
49
|
50
|
40
|
42
|
34
|
33
|
|
| Other Non-Cash Items |
3 654
|
76
|
(129)
|
(89)
|
(38)
|
(14)
|
(47)
|
(109)
|
|
| Cash Taxes Paid |
(1)
|
0
|
0
|
1
|
1
|
1
|
6
|
7
|
|
| Cash Interest Paid |
0
|
0
|
2
|
6
|
10
|
15
|
18
|
18
|
|
| Change in Working Capital |
3
|
(137)
|
(6)
|
103
|
21
|
(49)
|
(327)
|
(338)
|
|
| Cash from Operating Activities |
(215)
N/A
|
(295)
-38%
|
(402)
-36%
|
(197)
+51%
|
(304)
-54%
|
(709)
-134%
|
(790)
-11%
|
(605)
+23%
|
|
| Investing Cash Flow | |||||||||
| Capital Expenditures |
(173)
|
(345)
|
(280)
|
(392)
|
(383)
|
(192)
|
(214)
|
(255)
|
|
| Other Items |
(1 863)
|
(1 993)
|
(366)
|
534
|
851
|
176
|
282
|
163
|
|
| Cash from Investing Activities |
(2 036)
N/A
|
(2 338)
-15%
|
(646)
+72%
|
142
N/A
|
468
+230%
|
(16)
N/A
|
68
N/A
|
(92)
N/A
|
|
| Financing Cash Flow | |||||||||
| Net Issuance of Common Stock |
3 702
|
2 849
|
(51)
|
(41)
|
(33)
|
(37)
|
(32)
|
792
|
|
| Net Issuance of Debt |
(10)
|
139
|
75
|
155
|
269
|
391
|
333
|
140
|
|
| Other |
(54)
|
(50)
|
(32)
|
(190)
|
(164)
|
(15)
|
(17)
|
(27)
|
|
| Cash from Financing Activities |
3 638
N/A
|
2 938
-19%
|
(8)
N/A
|
(76)
-847%
|
72
N/A
|
340
+371%
|
284
-16%
|
905
+219%
|
|
| Change in Cash | |||||||||
| Effect of Foreign Exchange Rates |
(67)
|
38
|
139
|
70
|
10
|
(20)
|
5
|
23
|
|
| Net Change in Cash |
1 321
N/A
|
343
-74%
|
(917)
N/A
|
(61)
+93%
|
247
N/A
|
(405)
N/A
|
(433)
-7%
|
232
N/A
|
|
| Free Cash Flow | |||||||||
| Free Cash Flow |
(387)
N/A
|
(640)
-65%
|
(681)
-6%
|
(589)
+14%
|
(686)
-17%
|
(901)
-31%
|
(1 004)
-11%
|
(860)
+14%
|
|